L’epidemic of monkey pox gain territory. If the emergency committee of theWorld Health Organization (WHO) on the monkeypox is due to meet this Thursday, July 21, in Francethe bar of one thousand cases has been exceeded.
As a result, the High Authority for Health (HAS) recommends the vaccination of the most exposed groups: “Men who have sex with men and trans people who have multiple partners, people in a situation of prostitution, professionals working in places of sexual consumption”.
Read also :
Monkey pox: 11,068 cases of monkeypox virus confirmed, WHO emergency committee to meet on July 21
HAS recalls that the vaccination schedule consists of two doses, 28 days apart, reduced to one dose for people who have already been vaccinated against smallpox, and extended to three doses depending on the case for immunocompromised people.
“For this vaccination, we use third-generation vaccines marketed since 2013, by the Danish biotechnology company Bavarian Nordic, under the name of Imvanex® in Europe, Jynneos® in the United States or Imvamune® in Canada. This vaccine , said to be alive, contains a weakened version of the virusthat of the Ankara strain vaccinia, close to the smallpox virus, and it is effective against monkeypox thanks to the cross-protection between the different pox viruses”informs the site vih.org.
A vaccine who can nevertheless give birth toSide effects according to the Food and Drug Administration (FDA), US Food and Drug Administration: namely pain, swelling, inflammation or itching at the injection site. But also muscle aches, headaches, fatigue, nausea, fever, and chills.
Smallpox vaccines usually leave a scar at the injection site. But this is not the case for the Jynneos.